Biogen (NASDAQ:BIIB – Free Report) had its target price lowered by Truist Financial from $220.00 to $210.00 in a research ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Biogen (NASDAQ:BIIB – Free Report) had its price target decreased by BMO Capital Markets from $156.00 to $139.00 in a report ...

TD Cowen analysts adjusted their outlook on Biogen (NASDAQ:BIIB) shares, reducing the price target to $200 from the previous $275, while sustaining a Buy rating on the stock. The revision reflects ...

Biogen Inc. (NASDAQ:BIIB) shares tumbled to a 52-week low of $139.7, reflecting a stark downturn in the biotechnology firm's market performance. With a market capitalization of $20.38 billion and a ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 ...

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Biogen (BIIB) to $139 from $156 and keeps a Market Perform rating on the ...

Biogen Pharmachem Industries Ltd share price was down by -0.93% from the previous closing price of ₹1.07. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

A 16.73% drop is evident in the current average compared to the previous average price target of $257.94. Interpreting Analyst Ratings: A Closer Look The standing of Biogen among financial experts ...

is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM ...